Thomas VD, Yang FC, Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol 2005;53:346-51 (August) (DOI:10.1016/j.jaad.2005.04.011);Biologics in psoriasis: A quick reference guide

Journal of the American Academy of Dermatology

Volumn 53, Issue 2, 2005, Pages 346-351

  Thomas, Valencia D ^a   Yang, F Clarissa ^a   Kvedar, Joseph C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

ABDOMINAL PAIN; ALLERGIC REACTION; ARTHRALGIA; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; CONFUSION; COUGHING; DISEASE EXACERBATION; DIZZINESS; FATIGUE; FEVER; FLU LIKE SYNDROME; GENERAL PRACTITIONER; HEADACHE; HUMAN; HYPERSENSITIVITY; INFECTION; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; PANCYTOPENIA; PARESTHESIA; PHARYNGITIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RESPIRATORY TRACT DISEASE; REVIEW; SEPSIS; SIDE EFFECT; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; TUBERCULOSIS; UNITED STATES;

EID: 22144444168     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.02.067     Document Type: Erratum

References (27)

1. U. Chaudhari P. Romano L. Mulcahy L. Dooley D. Baker A. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial Lancet 357 2001 1842 1847
2. A.L. Chew A. Bennett C.H. Smith J. Barker B. Kirkham Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab Br J Dermatol 151 2004 492 496
3. C.N. Ellis G.G. Krueger Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes N Engl J Med 345 2001 248 255
4. Facts—psoriasis. National Psoriasis Foundation; 2002. Available at www.psoriasis.org/facts/psoriasis/ . Accessed December 15, 2004.
5. M.A. Gardam E.C. Keystone R. Menzies S. Manners E. Skamene R. Long Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect Dis 3 2003 148 155
6. K.B. Gordon K.A. Papp T.K. Hamilton P.A. Walicke W. Dummer N. Li Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial JAMA 290 2003 3073 3080 Erratum in: JAMA 2004;291:1070
7. K.B. Gordon A.K. Vaishnaw J. O'Gorman J. Haney A. Menter Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts Arch Dermatol 139 2003 1563 1570
8. A.B. Gottlieb J.G. Krueger R. Bright M. Ling M. Lebwohl S. Kang Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis J Am Acad Dermatol 42 2000 428 435
9. A.B. Gottlieb T.B. Casale E. Frankel B. Goffe N. Lowe H.D. Ochs CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study J Am Acad Dermatol 49 2003 816 825
10. A.B. Gottlieb U. Chaudhari L.D. Mulcahy S. Li L.T. Dooley D.G. Baker Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis J Am Acad Dermatol 48 2003 829 835
11. S. Jablonska S. Majewski On the immunopathogenesis of psoriasis Arch Dermatol 137 2001 229 230
12. B. Kirby C.E.M. Griffiths Novel immune-based therapies for psoriasis Br J Dermatol 146 2002 546 551
13. G.G. Krueger K.P. Callis Development and use of alefacept to treat psoriasis J Am Acad Dermatol 49 suppl 2 2003 S87 S97
14. J.G. Krueger The immunologic basis for the treatment of psoriasis with new biologic agents J Am Acad Dermatol 46 2002 1 23
15. M. Lebwohl Combining the new biologic agents with our current psoriasis armamentarium J Am Acad Dermatol 49 suppl 2 2003 S118 S124
16. M. Lebwohl E. Christophers R. Langley J.P. Ortonne J. Roberts C.E. Griffiths An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis Arch Dermatol 139 2003 719 727
17. M. Lebwohl S.K. Tyring T.K. Hamilton D. Toth S. Glazer N.H. Tawfik A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 349 2003 2004 2013
18. C.L. Leonardi Efalizumab: an overview J Am Acad Dermatol 49 suppl 2 2003 S98 S104
19. N. Mohan E.T. Edwards T.R. Cupps P.J. Oliverio G. Sandberg H. Crayton Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides Arthritis Rheum 44 2001 2862 2869
20. T. Patel K.B. Gordon Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis Dermatol Ther 17 2004 427 431
21. Raptiva (efalizumab) package insert 2003 Genentech, Inc San Francisco, CA
22. N. Scheinfeld Adalimumab (HUMIRA): a review J Drugs Dermatol 2 2003 375 377
23. P. Singri D.P. West K.B. Gordon Biologic therapy for psoriasis Arch Dermatol 183 2002 657 663
24. US Food and Drug Administration Web site. Amevive (alefacept) package insert. Cambridge, MA: Biogen, Inc; 2003. Available at: http://www.fda.gov/cder/foi/label/2003/alefbio013003LB.htm .
25. US Food and Drug Administration Web site. Enbrel (etanercept) package insert. Seattle, WA: Immunex Corp; 2004. Available at: www.fda.gov/cder/foi/label/2002/etanimm091202LB.pdf . Accessed April 13, 2005.
26. US Food and Drug Administration Web site. Remicade (infliximab) package insert. Malvern, PA: Centocor Inc; 2002. Available at: www.fda.gov/cder/foi/label/2002/inflcen022702LB.pdf . Accessed April 13, 2005.
27. US Food and Drug Administration Web site. Humira (adalimumab) package insert. North Chicago, IL: Abbott Laboratories; 2002. Available at: www.fda.gov/cder/foi/label/2002/adalabb123102LB.pdf . Accessed April 13, 2005.